JP2008526807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526807A5 JP2008526807A5 JP2007549870A JP2007549870A JP2008526807A5 JP 2008526807 A5 JP2008526807 A5 JP 2008526807A5 JP 2007549870 A JP2007549870 A JP 2007549870A JP 2007549870 A JP2007549870 A JP 2007549870A JP 2008526807 A5 JP2008526807 A5 JP 2008526807A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- oxy
- physiologically acceptable
- acceptable solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- -1 cyanomethyl Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500406A GB0500406D0 (en) | 2005-01-10 | 2005-01-10 | Novel compounds |
| GB0518775A GB0518775D0 (en) | 2005-09-14 | 2005-09-14 | Novel compounds |
| PCT/EP2006/000150 WO2006072600A1 (en) | 2005-01-10 | 2006-01-09 | Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526807A JP2008526807A (ja) | 2008-07-24 |
| JP2008526807A5 true JP2008526807A5 (https=) | 2009-02-12 |
Family
ID=36051466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549870A Withdrawn JP2008526807A (ja) | 2005-01-10 | 2006-01-09 | 炎症性及びアレルギー性症状の治療に使用するためのアンドロスタン１７−アルファ−カルボネート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090124588A1 (https=) |
| EP (1) | EP1836215B1 (https=) |
| JP (1) | JP2008526807A (https=) |
| AT (1) | ATE405576T1 (https=) |
| DE (1) | DE602006002366D1 (https=) |
| ES (1) | ES2312104T3 (https=) |
| WO (1) | WO2006072600A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841780B1 (en) * | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| GB0523251D0 (en) * | 2005-11-15 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
| MX2008013411A (es) | 2006-04-20 | 2008-11-04 | Glaxo Group Ltd | Nuevos compuestos. |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520684A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| AR076373A1 (es) | 2009-04-24 | 2011-06-08 | Glaxo Group Ltd | N-pirazolil carboxamidas como inhibidores de canales de calcio |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| RS54286B1 (sr) | 2010-09-08 | 2016-02-29 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| US9156791B2 (en) | 2010-10-21 | 2015-10-13 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| RU2016112268A (ru) | 2013-10-17 | 2017-11-22 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Ингибитор PI3K для лечения респираторного заболевания |
| US20170100385A1 (en) | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
| US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US6172054B1 (en) * | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| DE69813605T2 (de) * | 1997-10-01 | 2004-02-12 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuranderivate |
| US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| EP1841780B1 (en) * | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
-
2006
- 2006-01-01 US US11/813,230 patent/US20090124588A1/en not_active Abandoned
- 2006-01-09 ES ES06700486T patent/ES2312104T3/es not_active Expired - Lifetime
- 2006-01-09 JP JP2007549870A patent/JP2008526807A/ja not_active Withdrawn
- 2006-01-09 EP EP06700486A patent/EP1836215B1/en not_active Expired - Lifetime
- 2006-01-09 DE DE602006002366T patent/DE602006002366D1/de not_active Expired - Lifetime
- 2006-01-09 AT AT06700486T patent/ATE405576T1/de not_active IP Right Cessation
- 2006-01-09 WO PCT/EP2006/000150 patent/WO2006072600A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526807A5 (https=) | ||
| JP2008526806A5 (https=) | ||
| DE60308997T2 (de) | Formulierungen zur inhalation | |
| DE60131750T3 (de) | 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester als entzündungshemmendes arzneimittel | |
| DE60226334T2 (de) | Neue antiphlogistische androstan derivate - 17-carboxy-lactone substituiert mit einer aryl-carboxylic estergruppe in der 17.alpha.-stelle | |
| US6537983B1 (en) | Anti-inflammatory androstane derivatives | |
| US20120142651A1 (en) | Method of treatment of allergic rhinitis | |
| JP2006502172A (ja) | 抗炎症性または抗アレルギー性アンドロスタン複合体 | |
| WO2003072592A1 (en) | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents | |
| JP2005523267A (ja) | 水性液体担体中にアンドロスタン誘導体及び可溶化剤を含有する医薬製剤 | |
| US6777399B2 (en) | Anti-inflammatory androstane derivative compositions | |
| JP2005508368A (ja) | 高コレステロール濃度に関連した疾患の治療方法 | |
| JP2005537278A (ja) | 抗炎症性または抗アレルギー性アンドロスタン複合体 | |
| US20220106351A1 (en) | Heterodimer compositions and methods for the treatment of ocular disorders | |
| US20050152845A1 (en) | Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form | |
| US20070015741A1 (en) | Novel prodrugs of estradiol | |
| JP2002541153A5 (https=) | ||
| US20250074935A1 (en) | Heterodimer compositions and methods for the treatment of ocular disorders | |
| US9670246B2 (en) | Process for the esterification of a carbothioic acid |